Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration

Clinical Pharmacokinetics

Volumn 54, Issue 1, 2015, Pages 117-127

  Wagner, Christian ^a   Pan, Yuzhuo ^a   Hsu, Vicky ^a   Grillo, Joseph A ^a   Zhang, Lei ^a   Reynolds, Kellie S ^a   Sinha, Vikram ^a   Zhao, Ping ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM;

COMPUTER SIMULATION; DRUG INTERACTIONS; HUMANS; METABOLISM; MODELS, BIOLOGICAL; PHARMACOKINETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84928887973     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0188-4     Document Type: Article

References (13)

1. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92:50–61.
2. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2014;51:45–73.
3. Huang SM, Abernethy DR, Wang Y, Zhao P, Zineh I. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 2013;102:2912–23.
4. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89:259–67.
5. Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther. 2012;92:17–20.
6. Sinha V, Zhao P, Huang SM, Zineh I. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. Clin Pharmacol Ther. 2014;95:478–80.
7. Vieira MD, Kim MJ, Apparaju S, Sinha V, Zineh I, Huang SM, Zhao P. PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin Pharmacol Ther. 2014;95:550–7.
8. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for assessment of drug–drug interactions. Drug Metab Dispos. 2011;39:170–3.
9. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab Pharmacokinet. 2009;24:53–75.
10. Application of PBPK modeling to support dose selection: public meeting March 10, 2014. http://www.regulations.gov/#!docketDetail;D=FDA-2014-N-0129. Accessed 29 Aug 2014.
11. Peters SA, Schroeder PE, Giri N, Dolgos H. Evaluation of the use of static and dynamic models to predict drug–drug interaction and its associated variability: impact on drug discovery and early development. Drug Metab Dispos. 2012;40:1495–507.
12. FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects. 2013. http://www.fda.gov/drugs/drugsafety/ucm371017.htm. Accessed 17 July 2014.
13. Ke AB, Zamek-Gliszcznski MJ, Higgins JW, Hall SD. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014;95:473–6.